Mehmet Fuat Eren

Survival analysis and prognostic factors for neuroendocrine tumors in Turkey.

BACKGROUND This study aimed to determine the demographical distribution, survival and prognostic factors for neuroendocrine tumors monitored in our clinic. MATERIALS AND METHODS Data for 52 patients who were admitted to Cumhuriyet University Medical Faculty Training Research and Practice Hospital Oncology Center between 2006 and 2012 and were diagnosed and treated for neuroendocrine tumors were investigated. RESULTS Of the total, 30 (58%) were females and 22 (42%) were males. The localization of the disease was gastroenteropancreatic in 29 (56%) patients and other sites in 23 (44%). The most frequently involved organ in the gastroenteropancreatic system was the stomach (n=10, 19%) and the most frequently involved organ in other regions was the lungs (n=10, 19%). No correlation was found between immunohistochemical staining for proteins such as chromogranin A, synaptophysin, and NSE and the grade of the tumor. The patients were followed-up at a median of 24 months (1-90 months). The three-year overall survival rate was 71%: 100% in stage I, 88% in stage II, 80% in stage III, and 40% in stage IV. The three-year survival rate was 78% in tumors localized in the gastroenteropancreatic region, and 54% in tumors localized in other organs. In the univariate analysis, gender, age, performance status of the patients, grade, localization, surgical treatment, and neutrophil/ lymphocyte ratio (≤ 5 versus >5) affected the prognosis of the patients. CONCLUSIONS Most of the tumors were localized in the gastroenteropancreatic region, and the three-year survival rate in tumors localized in this region was better than the tumors localized in other sites. Surgical treatment was a positive independent prognostic factor, whereas Grade 3 and a neutrophil/lymphocyte ratio of >5 were negative independent prognostic factors.

A Case of Multifocal Skin Metastases from Lung Cancer Presenting with Vasculitic-type Cutaneous Nodule.

Although cutaneous metastasis occurs usually at the terminal stage of the disease, it may be rarely concurrent with the diagnosis and may also present as the first sign of the illness. A 55-year-old male patient presented with vasculitic-type cutaneous nodular lesions and a necrotic distal phalangeal lesion developed over the last month. He was a tradesman and smoked 40 packets year. On physical examination, he was found to have multiple cutaneous lesions on the skin of the face, limbs, neck, scalp, dorsal side, fingers, subungual side, right leg, and feet. A skin lesion punch biopsy was performed and squamous cell carcinoma metastasis was detected. He was diagnosed as having squamous cell lung cancer with bronchoscopic biopsy. Although it is very rare, cutaneous metastases that is concurrent with the diagnosis of lung cancer may be the first sign of the disease. In patients with suspicious skin lesions, the patients age, smoking history, and other symptoms should be evaluated and a biopsy should be performed.

Lack of Impact of Age on Acute Side Effects and Tolerance of Curative Radiation Therapy

AIM The aim of this study was to determine the impact of age on the occurrence, severity, and timing of acute side effects related to radiotherapy. MATERIALS AND METHODS We analysed the data of 423 patients. RESULTS Of the patients, 295 (70%) were under the age of 65 (group 1) and 128 (30%) were over the age of 65 (group 2). The frequencies of radiotherapy-induced side effects were 89% in group 1 and 87% in group 2 (p=0.286). The mean times to occurrence were 2.5±0.1 weeks in group 1 and 2.2±0.1 weeks in group 2 (p=0.013). Treatment was ended in 2% of patients in group 1 and 6% of those in group 2 (p=0.062). Treatment interruption was identified in 18% of patients in group 1 and 23% in group 2 (p=0.142). Changes in performance status were greater in older patients (p=0.013). There were no significant differences according to the frequency or severity of side effects, except skin and genitourinary complications, between the groups. CONCLUSIONS Early normal tissue reactions were not higher in older versus younger patients, though there was a tendency towards an earlier appearance.

Association between Molecular Subtypes and Survival in Patients with Breast Cancer

Background : Aim of this study is to classify intrinsic subtypes and evaluate the differences in clinical/pathological characteristics and survival outcomes among the molecular types. Patients and Methods : Breast cancer subtypes were classified according to the 2013 St. Gallen Consensus. Five molecular subtypes were determined, Luminal A, Luminal B-like HER2 negative, Luminal B-like HER2 positive, HER2 positive, and triple negative. Data was obtained from the records of patients with invasive breast cancer retrospectively. The differences in clinical/pathological parameters, overall survival and disease-free survival among the molecular subtypes were analyzed. The Kaplan-Meier method, log-rank test and Cox regression tests were used to compare groups. Results : The median follow-up period is 48 months. The Luminal B-HER2 negative was the most prevalent type (26.6%). Patient demographics, tumor characteristics and survival data were analyzed. The Luminal A and Luminal B-HER2 negative subtypes had significantly higher overall survival and disease-free survival rates. Multivariate Cox analysis revealed that tumor stage, more than 3 positive axillary lymph node involvement, and breast cancer subtype as significant factors for overall survival and disease-free survival ( p<0.05 ). Triple Negative subtype had a higher relative hazard of local recurrence and distant metastasis (HR=2.69, 95% CI=1.47; 4.95). Conclusions : Breast cancer subtype has significant impact on overall survival and disease-free survival rates. While Luminal A and luminal B HER2 negative subtypes have better outcome, triple negative and HER2- subtypes remain poor.

Abstract P3-12-20: The impact of everolimus on radiation-induced pulmonary fibrosis in wistar albino rats: Results of an experimental study

38th Annual CTRC-AACR San Antonio Breast Cancer Symposium -- DEC 08-12, 2015 -- San Antonio, TX

Mide kanserli hastalarda adjuvan kemoradyoterapi: Tek merkez deneyimi

Giris ve Amac: Bu calismada, adjuvan kemoradyoterapi ile tedavi edilen mide kanserli hastalarin sagkalim analizi, tedavi yan etkileri ve sagkalimi etkileyen prognostik faktorlerin incelemesi amaclandi. Gerec ve Yontem: Calismada Cumhuriyet Universitesi Tip Fakultesi Arastirma ve Uygulama Hastanesi Onkoloji Merkezinde takip edilen 90 mide kanserli hasta verileri retrospektif olarak incelendi. Bulgular: Calismada 68 (%76) erkek, 22 (%24) kadin toplam 90 hastanin verileri analiz edildi. Ortanca takip suresi 19 ay (4-105 ay) idi. Iki yillik genel sagkalim ve hastaliksiz sagkalim sirasiyla %62 ve %58 idi. Tek degiskenli analizde hastalarin sagkalimini grade (p:0,039), T evre (p:0,001), N evre (p:0,020), kilo kaybi (p: 0,001), ECOG performans durumu (p:0,002), anemi (p:0,019), hipoalbunemi (p:0,001) etkilerken, cok degiskenli analizde bagimsiz prognostik faktorler kilo kaybi (p:0,008), T evresi (p:0,024) ve ECOG performans durumu (p:0,033) idi. Hastalarda en sik gorulen yan etkiler; bulanti-kusma 66 (%73), dispepsi 52 (%58), anemi 45 (%50), notropeni 36 (%40), ishal 34 (%38) ve kilo kaybi 29 (%32) hastada goruldu. Sonuc: Bu calismada, adjuvan kemoradyoterapi uygulanan mide kanserli hastalarin genel ve hastaliksiz sagkalimi literatur ile benzer sonuclar gostermistir. Bu hasta grubunun en onemli prognostik faktorleri ise kilo kaybi, T evresi ve ECOG performans durumu olarak belirlendi.

Baş boyun kanserlerinde prognoz: Hasta ve tedaviyle ilişkili faktörlerin önemi

Department of Radiation Oncology, Faculty of Medicine, Cumhuriyet University, Sivas, Turkey Department of Radiation Oncology, Dr. Abdurrahman Yurtarslan Ankara Oncology Training and Research Hospital, Ankara, Turkey Department of Medical Oncology, Faculty of Medicine, Cumhuriyet University, Sivas, Turkey Department of Nuclear Medicine, Faculty of Medicine, Cumhuriyet University, Sivas, Turkey Clinical Research / Klinik Araflt›rma